These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 29341831)
1. Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. Anderson K; Ismaila N; Flynn PJ; Halabi S; Jagannath S; Ogaily MS; Omel J; Raje N; Roodman GD; Yee GC; Kyle RA J Clin Oncol; 2018 Mar; 36(8):812-818. PubMed ID: 29341831 [TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. Kyle RA; Yee GC; Somerfield MR; Flynn PJ; Halabi S; Jagannath S; Orlowski RZ; Roodman DG; Twilde P; Anderson K; J Clin Oncol; 2007 Jun; 25(17):2464-72. PubMed ID: 17515569 [TBL] [Abstract][Full Text] [Related]
3. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912 [TBL] [Abstract][Full Text] [Related]
4. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. Van Poznak C; Somerfield MR; Barlow WE; Biermann JS; Bosserman LD; Clemons MJ; Dhesy-Thind SK; Dillmon MS; Eisen A; Frank ES; Jagsi R; Jimenez R; Theriault RL; Vandenberg TA; Yee GC; Moy B J Clin Oncol; 2017 Dec; 35(35):3978-3986. PubMed ID: 29035643 [TBL] [Abstract][Full Text] [Related]
5. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. Berenson JR; Hillner BE; Kyle RA; Anderson K; Lipton A; Yee GC; Biermann JS; J Clin Oncol; 2002 Sep; 20(17):3719-36. PubMed ID: 12202673 [TBL] [Abstract][Full Text] [Related]
6. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. Dhesy-Thind S; Fletcher GG; Blanchette PS; Clemons MJ; Dillmon MS; Frank ES; Gandhi S; Gupta R; Mates M; Moy B; Vandenberg T; Van Poznak CH J Clin Oncol; 2017 Jun; 35(18):2062-2081. PubMed ID: 28618241 [TBL] [Abstract][Full Text] [Related]
7. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. Terpos E; Morgan G; Dimopoulos MA; Drake MT; Lentzsch S; Raje N; Sezer O; García-Sanz R; Shimizu K; Turesson I; Reiman T; Jurczyszyn A; Merlini G; Spencer A; Leleu X; Cavo M; Munshi N; Rajkumar SV; Durie BG; Roodman GD J Clin Oncol; 2013 Jun; 31(18):2347-57. PubMed ID: 23690408 [TBL] [Abstract][Full Text] [Related]
8. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. Himelstein AL; Foster JC; Khatcheressian JL; Roberts JD; Seisler DK; Novotny PJ; Qin R; Go RS; Grubbs SS; O'Connor T; Velasco MR; Weckstein D; O'Mara A; Loprinzi CL; Shapiro CL JAMA; 2017 Jan; 317(1):48-58. PubMed ID: 28030702 [TBL] [Abstract][Full Text] [Related]
9. Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials. Jiang L; Cui X; Ma H; Tang X J Orthop Surg Res; 2021 Jun; 16(1):400. PubMed ID: 34158101 [TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates in multiple myeloma: a network meta-analysis. Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688 [TBL] [Abstract][Full Text] [Related]
11. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. Van Poznak CH; Temin S; Yee GC; Janjan NA; Barlow WE; Biermann JS; Bosserman LD; Geoghegan C; Hillner BE; Theriault RL; Zuckerman DS; Von Roenn JH; J Clin Oncol; 2011 Mar; 29(9):1221-7. PubMed ID: 21343561 [TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
14. Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis. Huang SY; Yoon SS; Shimizu K; Chng WJ; Chang CS; Wong RS; Gao S; Wang Y; Gordon SW; Glennane A; Min CK Adv Ther; 2020 Jul; 37(7):3404-3416. PubMed ID: 32524500 [TBL] [Abstract][Full Text] [Related]
15. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. Hillner BE; Ingle JN; Berenson JR; Janjan NA; Albain KS; Lipton A; Yee G; Biermann JS; Chlebowski RT; Pfister DG J Clin Oncol; 2000 Mar; 18(6):1378-91. PubMed ID: 10715310 [TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of bone-modifying agents among multiple myeloma patients: A retrospective cohort study. Billias C; Langer M; Ursu S; Schorr R J Oncol Pharm Pract; 2022 Apr; 28(3):523-529. PubMed ID: 33593137 [TBL] [Abstract][Full Text] [Related]
18. Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials. Chen C; Li R; Yang T; Ma L; Zhou S; Li M; Zhou Y; Cui Y Clin Ther; 2020 Aug; 42(8):1494-1507.e1. PubMed ID: 32718784 [TBL] [Abstract][Full Text] [Related]
19. Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis. Bozzo A; Deng J; Abbas U; Bhasin R; Deodat M; Wariach S; Sanger S; Axelrod D; Masrouha K; Turcotte R; Wilson D; Ghert M Clin Orthop Relat Res; 2021 Sep; 479(9):2047-2057. PubMed ID: 33835092 [TBL] [Abstract][Full Text] [Related]
20. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]